Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Fineline Cube Dec 31, 2025
Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Fineline Cube Dec 31, 2025
Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Fineline Cube Dec 31, 2025
Company Deals

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline

Fineline Cube Dec 31, 2025
Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Fineline Cube Dec 31, 2025
Company Drug

Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy

Fineline Cube Dec 31, 2025
Company Deals Digital

JD Healthcare Forges Partnerships with Top Medical Device Firms at CMEF

Fineline Cube Apr 15, 2024

The China International Medical Equipment Fair (CMEF), which took place last week in Shanghai, was...

Policy / Regulatory

FDA Advisory Committee Backs MRD as Accelerated Approval Endpoint for Multiple Myeloma

Fineline Cube Apr 15, 2024

The Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) has...

Company

I-Mab CEO Outlines Streamlined US Entity’s Focus and Potential for In-Licensing

Fineline Cube Apr 15, 2024

I-Mab (NASDAQ: IMAB), a biopharmaceutical company that recently restructured into separate US and Chinese entities,...

Policy / Regulatory

Hainan Medical Zone Launches ‘Lecheng Global Special Medical Insurance’ for Wider Drug Access

Fineline Cube Apr 15, 2024

The Hainan Boao Lecheng International Medical Tourism Pilot Zone has launched the “Lecheng Global Special...

Company Drug

Hengrui Pharmaceuticals Gets NMPA Approval for Clinical Study of CDK 4/6 Inhibitor Combo in Breast Cancer

Fineline Cube Apr 15, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company in China, has announced...

Company

Blue Shield Biotech Faces Bankruptcy Proceedings After Missing Debt Payments

Fineline Cube Apr 15, 2024

The Nanjing Qixia District People’s Court has accepted a bankruptcy liquidation case for Blue Shield...

Company Medical Device

Roche and Eli Lilly’s Elecsys pTau217 Blood Test Earns FDA Breakthrough Designation for Alzheimer’s Detection

Fineline Cube Apr 15, 2024

The U.S. Food and Drug Administration (FDA) has granted a breakthrough device designation for Elecsys...

Company Drug

3SBio Secures NMPA Approval for Pediatric Thrombopoietin Treatment of ITP

Fineline Cube Apr 15, 2024

3SBio Inc. (HKG: 1530), a leading biopharmaceutical company based in China, has announced that it...

Company Deals Medical Device

Bayer Partners with Hologic to Develop Contrast-Enhanced Mammography Solution for Breast Cancer Diagnosis

Fineline Cube Apr 15, 2024

Bayer (ETR: BAYN), a multinational pharmaceutical and life sciences company headquartered in Germany, has announced...

Company Drug

AbbVie’s Aquipta/Qulipta Shows Promise in Migraine Prevention Trial

Fineline Cube Apr 15, 2024

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, last week released interim results from a...

Company Drug

Laekna’s Anti-ActRIIA Antibody LAE102 Clears FDA Hurdle for Obesity Treatment Trial

Fineline Cube Apr 15, 2024

Sino-American biotech firm Laekna has announced that it has received clinical trial approval from the...

Policy / Regulatory

NHSA Reports 2023 Milestones in Basic Medical Insurance Participation and Financials

Fineline Cube Apr 12, 2024

The National Healthcare Security Administration (NHSA) has published its annual “Healthcare Security Development Statistical Bulletin”...

Company

Sanofi Explores Sale of Amunix Pharmaceuticals as It Shifts Focus to Immunology

Fineline Cube Apr 12, 2024

Sanofi (NASDAQ: SNY), the France-based pharmaceutical giant, is reportedly in talks with potential buyers for...

Company Drug

AstraZeneca’s Fasenra Gains FDA Approval for Pediatric Severe Asthma Treatment

Fineline Cube Apr 12, 2024

AstraZeneca (AZ; NASDAQ: AZN) has secured an indication extension from the U.S. Food and Drug...

Company Drug

Qilu Pharmaceutical Gets NMPA Green Light for Generic Romiplostim for ITP Treatment

Fineline Cube Apr 12, 2024

The National Medical Products Administration (NMPA) in China has granted marketing approval to Qilu Pharmaceutical...

Company Drug

Suzhou Zelgen Receives NMPA Approval for Jacktinib Cream Trial in Vitiligo Patients

Fineline Cube Apr 12, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received approval from...

Company Drug

Haisco Pharmaceutical Gets NMPA Green Light for HSK31858 COPD Trial

Fineline Cube Apr 12, 2024

Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a Chinese pharmaceutical company, has announced that it...

Company Deals

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences in a $4.9 Billion Deal

Fineline Cube Apr 12, 2024

In a multibillion-dollar deal within the biotechnology sector, Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), a leader...

Company Drug

Teva’s Ajovy Achieves Positive Results in Phase III Migraine Prevention Trial in China

Fineline Cube Apr 12, 2024

Teva Pharmaceutical Industries Ltd (NYSE: TEVA), headquartered in Israel, has announced positive results from a...

Company Deals Medical Device

LargeV Instrument’s IPO on STAR Board Halted Following Filing and Sponsorship Withdrawal

Fineline Cube Apr 12, 2024

The initial public offering (IPO) of LargeV Instrument Corp., Ltd to the Shanghai Stock Exchange’s...

Posts pagination

1 … 312 313 314 … 603

Recent updates

  • Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
  • HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review
  • NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion
  • Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China
  • Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.